Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Where multidisciplinarity meets global collaboration — join us in Berlin, or online, for an event that promises to drive progress in oncology.
Staying updated with the latest advancements in cancer care has never been easier. Contribute to cutting-edge breast cancer science and present your studies at this prestigious international platform. We published three new titles last year: Breast Cancer, Gynaecological Tumours and Lymphomas - all written with young oncologists in mind. Join experts to explore cutting-edge insights into sarcoma and rare cancers: multidisciplinary care, molecular diagnostics, precision therapies, and research advancements to improve patient outcomes.
Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives and help secure the optimisation of patient care worldwide. The updated Antineoplastic Medicine Survey ANMS dataset shows that essential therapies remain out of reach for patients in most low and lower middle-income countries despite international efforts.
New indication concerns monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative CDpositive B-cell precursor ALL. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology. The Molecular Analysis for Precision Oncology Congress MAP is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics.
The ESMO Congress taking place September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand. According to two international studies presented at the ESMO Congress , women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer , do not face an increased risk of recurrence or developing new breast cancers.
